ImmunityBio Confirms Statistical Power in Pivotal Randomized BCG-Naïve NMIBC Trial to Detect Clinically Meaningful Differences Between ANKTIVA® Plus BCG Versu…

ImmunityBio, Inc. (NASDAQ: IBRX), a vertically integrated, commercial-stage immunotherapy company, today announced that based ...
Stocktwits on MSN

ImmunityBio says phase 2 bladder cancer trial has ‘statistical power’ – Anktiva-BCG advances toward filing

ImmunityBio (IBRX) said on Thursday that its QUILT-2.005 clinical trial evaluating Anktiva plus Bacillus Calmette-Guérin (BCG ...
Morningstar

ImmunityBio Advances First-Line BCG Naive NMIBC Program with Enrollment Exceeding Expectations and Positive Interim Analysis for ANKTIVA® Plus BCG

Enrollment of BCG naïve subjects (QUILT-2.005) receiving BCG alone versus BCG plus ANKTIVA exceeding expectations 85% enrolled with anticipated completion in Q2 2026 with BLA filing to U.S. Food and ...
ascopubs.org

Outcomes of additional BCG versus sequential gemcitabine + docetaxel in BCG-exposed high-risk non–muscle-invasive bladder cancer.

Clinical outcomes of chemotherapy with or without intravesical BCG in NMIBC patients: A Bayesian network meta-analysis. Baseline clinicopathologic variables of patients upon BCG exposed HR NMIBC ...
ascopubs.org

Treatment patterns with intravesical bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder cancer (NMIBC): A real-world data analysis.

Neoadjuvant cisplatin-based chemotherapy followed by selective bladder preservation chemoradiotherapy in muscle-invasive urothelial carcinoma of the bladder: Post hoc analysis of two prospective ...